Group 1 - The core point of the news is that China Universal Asset Management has announced a subscription limit for two of its funds, the China Universal Science and Technology Innovation Fund and the China Universal Medical Innovation Fund, starting from August 11, to protect existing investors and maintain stable operations [1] - The China Universal Science and Technology Innovation Fund, managed by Shao Jie, has achieved a return rate of 132.55% since inception, with an annualized return of 14.79% for Class A shares and 39.66% with an annualized return of 13.11% for Class C shares [1] - The China Universal Medical Innovation Fund, managed by renowned fund manager Ge Lan, has a return rate of 68.74% for Class A shares and 60.24% for Class C shares since inception, with annualized returns of 8.45% and 7.59% respectively [1] Group 2 - The China Universal Science and Technology Innovation Fund focuses on the technology innovation industry, with significant investments in sectors such as smart vehicles, advanced manufacturing processes, and self-developed chip IP [2] - The top ten holdings of the China Universal Science and Technology Innovation Fund include companies like Hengxuan Technology, Lanyin Technology, and Tencent Holdings, with total market values ranging from approximately 117 million to 350 million yuan [2] - The China Universal Medical Innovation Fund primarily invests in stocks related to medical innovation, with a focus on innovative pharmaceuticals and medical devices [2][4] Group 3 - The top ten holdings of the China Universal Medical Innovation Fund include companies such as Sanofi Pharmaceutical and WuXi AppTec, with market values ranging from approximately 324 million to 729 million yuan [4] - Other funds managed by different companies, such as ICBC Credit Suisse and Great Wall Fund, have also reported high returns this year, with notable investments in similar sectors [5][6]

Group 1 - The core point of the news is that China Europe Fund announced a limit on daily subscriptions for the China Europe Medical Innovation Fund to 100,000 yuan starting from August 11, 2025, to ensure stable fund operations and protect the interests of fund shareholders [1][2][3] - The China Europe Medical Innovation Fund, managed by fund manager Ge Lan, was established in February 2019 and primarily invests in stocks related to medical innovation [3][4] - As of mid-2023, the fund's total net asset value exceeded 8.2 billion yuan, with major investments in healthcare and manufacturing sectors, accounting for 46.41% and 41.99% of the total assets, respectively [5][6] Group 2 - The top ten holdings of the fund include companies such as Sanofi Pharmaceutical, Keren Biotechnology, and Kangfang Biotech, with the largest holding, Sanofi Pharmaceutical, showing a year-to-date increase of nearly 400% [4][6] - The fund's unit net value has been rising, reaching 1.6874 yuan, compared to a low of below 0.9 yuan a year ago [7][8] - The fund's outlook for the third quarter highlights optimism in the innovative drug sector, with expectations for global collaboration and important clinical data disclosures, as well as ongoing domestic policy support for high-quality drug development [8]

Group 1 - The core announcement from China Europe Fund is the suspension of large subscriptions, conversions, and regular investment for the China Europe Medical Innovation Equity Fund starting from August 11, 2025, with a daily limit of 100,000 yuan per account to ensure fund stability and protect the interests of fund shareholders [1][3][10] - The China Europe Medical Innovation Fund, established in February 2019 and managed by fund manager Ge Lan, primarily invests in stocks related to the medical innovation sector, aiming to achieve returns that exceed the performance benchmark while strictly controlling investment risks [1][3][5] - As of mid-2023, the fund's total net asset value exceeded 8.2 billion yuan, with major investments in healthcare and manufacturing sectors, accounting for 46.41% and 41.99% of the total assets, respectively [4][5] Group 2 - The top ten holdings of the fund include companies such as 3SBio, Kelun-Biotech, and Kangfang Biotech, with the largest holding, 3SBio, showing a remarkable increase of nearly 400% this year [4][6][8] - The fund's unit net value has been on the rise, reaching 1.6874 yuan, significantly up from below 0.9 yuan a year ago, reflecting the rebound in the innovative drug sector [7][8] - The fund's outlook for the third quarter highlights optimism in the innovative drug field, with expectations for global cooperation and important clinical data disclosures, alongside supportive domestic policies for high-quality development in innovative drugs [8]

Core Viewpoint - MSCI announced the results of its August index quarterly review, which includes the addition and removal of several stocks in the MSCI China Index, reflecting recent strong performance in sectors such as technology, innovative pharmaceuticals, and new consumption [1]. Summary by Category Additions to MSCI China Index - 14 stocks were added to the MSCI China Index, including notable companies such as: - Lao Pu Gold (06181) - WuXi AppTec (02268) - Meitu (01357) - NetEase Cloud Music (09899) - 3SBio (01530) - Horizon Robotics (09660) - Global Data (09698) - Kintor Pharmaceutical (06990) - 5 additional A-shares including: - Zhinan (300803.SZ) - CITIC Bank (601998.SH) - Giant Network (002558.SZ) - Ailis (688578.SH) - Jingwang Electronics (603228.SH) [1][3][5]. Removals from MSCI China Index - 17 stocks were removed from the MSCI China Index, including: - Hisense Home Appliances (00921) - Zhongsheng Holdings (00881) - Yingjia Wine (603198.SH) - Oriental Yuhong (002271.SZ) - 13 additional stocks including: - Supor (002032.SZ) - Chihong Zn & Ge (600497.SH) - Morning Light Co. (603899.5H) - and others [1][3][5]. Global Index Changes - The MSCI Global Standard Index added 42 stocks and removed 56 stocks, with the largest new additions being Rocket Lab (USA), SoFi Technologies (USA), and Affirm Holdings (USA) [5]. - The top three new additions to the MSCI Emerging Markets Index include CITIC Bank, Dian Swastatika Sentosa, and Lao Pu Gold [5].

Investment Rating - The report maintains an "Outperform" rating for the industry [1] Core Insights - There is an unmet clinical need in HR+/HER2- breast cancer (BC), which accounts for approximately 60-70% of all breast cancer cases globally [2][8] - New mechanism drugs are expected to extend chemotherapy-free survival for HR+/HER2- BC patients, with a focus on overcoming resistance to endocrine therapy (ET) and enhancing the efficacy of CDK4/6 inhibitors [2][40] - The report highlights the potential of various new target molecules and mechanisms to improve patient outcomes and expand market size [2][40] Summary by Sections 1. Unmet Clinical Needs in HR+/HER2- BC - HR+/HER2- BC is the most common subtype of breast cancer, with significant unmet clinical needs, especially for patients with specific mutations [2][8] - Current treatment options, including ET and CDK4/6 inhibitors, are limited for patients who progress after first-line therapy [2][40] 2. Endocrine Therapy: New Mechanism Molecules to Overcome Resistance - New generation oral SERDs and ER PROTACs are promising in overcoming resistance caused by ESR1 mutations [2][40] - The estrogen signaling pathway plays a critical role in breast cancer, and targeting this pathway is essential for effective treatment [13][48] 3. CDK Inhibitors: Partners in ET to Extend Treatment Duration - CDK4/6 inhibitors significantly improve progression-free survival (PFS) when combined with ET in first-line treatment [14][25] - There is a need for new mechanism molecules targeting the CDK-cyclin pathway to address resistance after first-line therapy [2][40] 4. Other New Target Molecules: Potential to Extend Chemotherapy-Free Survival - Activation of the PI3K/AKT/mTOR pathway is a common resistance mechanism in HR+/HER2- BC, with several products already approved for treatment [2][40] - New targets such as KAT6i and ADCs are expected to show advantages over chemotherapy and occupy significant positions in treatment sequences [2][40] 5. Company Analysis - Companies leading in the development of new mechanism drugs include BeiGene, Hansoh Pharmaceutical, Kelun-Botai Biopharmaceutical, and China National Pharmaceutical Group [2][40]

Core Insights - The latest net value of Zhongyin Innovation Medical Mixed A (007718) is 2.1723 yuan, reflecting a decline of 3.54%. The fund has shown a one-month return of 12.66%, a six-month return of 78.76%, and a year-to-date return of 80.53% [1]. Fund Performance - The fund ranks 684 out of 4457 in the one-month category, 23 out of 4316 in the six-month category, and 29 out of 4287 in the year-to-date category [1]. Holdings Overview - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 62.83%, with significant positions in companies such as: - Innovent Biologics (8.33%) - Kelun-Biotech (8.15%) - Heng Rui Medicine (8.08%) - CanSino Biologics (8.07%) - New Horizon Health (6.13%) - Bai Li Tianheng (5.99%) - BeiGene (5.97%) - Hansoh Pharmaceutical (4.15%) - Rongchang Biologics (4.05%) - CanSino Biologics-B (3.91%) [1]. Fund Manager Background - Zheng Ning, the fund manager, has a master's degree and has previously held positions at Taikang Asset Management and Zhonggeng Fund Management. He joined Zhongyin Fund Management in 2022 and has been managing the Zhongyin Innovation Medical Mixed Fund since July 1, 2022 [2].

Group 1: Macro Strategy and Tariff Impact - The report highlights the significant changes in the U.S. non-farm data as a reflection of the post-pandemic "K-shaped economy" differentiation, raising doubts about the effectiveness of current economic statistics [3][23] - It discusses the evolving framework of the U.S. "reciprocal tariffs" policy, which is becoming clearer with three tiers based on country agreements, affecting various industries [23][24] - The report suggests that the impact of tariffs on consumer prices in the U.S. is just beginning to manifest, with potential inflation risks remaining due to the ongoing tariff framework and domestic demand stimulation from tax cuts [25][26] Group 2: Chemical Industry - Soda Ash Investment Opportunities - The soda ash industry has about 30% of its capacity being outdated, with 10% of the capacity having energy consumption and emissions below benchmark levels [4] - The report emphasizes the importance of focusing on companies with cost advantages, particularly those using natural soda ash methods, which are more energy-efficient and cost-effective compared to synthetic methods [4] - Recommended companies include Boyuan Chemical, which is the largest domestic soda ash producer with a capacity of 6.8 million tons, and Zhongyan Chemical, which is expanding its capacity through new mining rights [4] Group 3: Pharmaceutical Industry - Kolun Biotechnology - Kolun Biotechnology's SKB264, a TROP2 ADC drug, is in the global phase III clinical trials and is considered to have blockbuster potential, with significant data expected in 2027 [5][36] - The drug has shown promising results in various indications, particularly in NSCLC, outperforming competitors in terms of progression-free survival [37][38] - The report indicates that SKB264 is positioned in the first tier of global competition, with a strong focus on its unique molecular design contributing to its efficacy and safety profile [37][38] Group 4: Electronics Industry - Lian De Equipment - Lian De Equipment has been awarded a contract for the 8.6 generation AMOLED production line, indicating its leading position in the OLED equipment market [18][27] - The company is expected to benefit from the growing demand for flexible AMOLED displays, particularly in foldable smartphones and high-end IT devices [28][29] - The report projects significant growth in the solid-state battery market, with Lian De Equipment actively developing equipment for this sector, indicating a strong future market potential [30][31] Group 5: Electronics Industry - Sunrock Electronics - Sunrock Electronics reported a sales revenue of 3.224 billion yuan in the first half of 2025, marking a year-on-year increase of 19.80% [32][33] - The company is experiencing growth in its automotive electronics and data center business, with significant contributions to its revenue from these sectors [34] - The report maintains a positive outlook on the company's profitability, projecting net profits of 1.05 billion yuan for 2025 and 1.28 billion yuan for 2026 [35]

Core Insights - The collaboration between the company and Merck focuses on the global development of TROP2 ADC, specifically the drug SKB264, which is recognized for its potential as a blockbuster product [1] - SKB264 is currently in the phase III global multi-center registration clinical trials for over ten solid tumor indications, with significant data expected to be disclosed in 2027 [1] - SKB264 has demonstrated superior efficacy in various patient populations, particularly in NSCLC, outperforming competitors in terms of median progression-free survival (mPFS) [2][3] Group 1: Product Development and Clinical Trials - SKB264 has entered the phase III clinical trial stage for multiple solid tumors, with Merck planning to disclose nine clinical trial data points in 2027 [1] - The drug has shown promising results in the first-line wild-type NSCLC population, achieving an mPFS of 15.0 months when combined with PD-1 monoclonal antibody KL-A167, surpassing other TROP2 ADCs [2] - In the PD-L1 TPS≥1% population, SKB264 achieved an mPFS of 17.8 months, and in the PD-L1 TPS<1% group, it reached 12.4 months, indicating its efficacy across different expression levels [2] Group 2: Competitive Landscape - SKB264 is positioned in the first tier of the global TROP2 ADC competition, alongside Gilead's Trodelvy and AstraZeneca/Daiichi Sankyo's Dato-DXd [1] - The molecular design of SKB264 provides it with better plasma stability and a longer half-life compared to Trodelvy, while being slightly shorter than Dato-DXd [1] Group 3: Future Directions and Market Potential - The rise of next-generation immunotherapy drugs suggests that IO+ADC combination therapies may become a key focus in the treatment of solid tumors [3] - The collaboration between BMS and BioNTech to develop a dual-specific antibody candidate highlights the commercial potential of combining IO with ADC therapies [3] Group 4: Financial Projections - The company forecasts revenues of 2.084 billion, 2.876 billion, and 4.663 billion yuan for the years 2025 to 2027, respectively, with net profits expected to improve significantly by 2027 [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 四川科倫博泰生物醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6990） 董事會會議通告 四 川 科 倫 博 泰 生 物 醫 藥 股 份 有 限 公 司（「本公司」）董 事 會（「董事會」）茲 通 告 謹 定 於2025年8月18日（星 期 一）舉 行 董 事 會 會 議，以（其 中 包 括）考 慮 及 批 准 本 公 司 及 其附屬公司截至2025年6月30日 止 六 個 月 之 中 期 業 績 及 其 發 佈，以 及 處 理 其 他 事 項。 中 期 業 績 發 佈 後，本 公 司 的 管 理 層 將 於 香 港╱北 京 時 間2025年8月18日（星 期 一） 下 午 八 時 正（即 格 林 威 治 標 準 時 間2 ...

Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Insights - The company's core product, SKB264, is positioned as a promising ADC targeting TROP2, with significant clinical trial progress and potential for commercialization [1][14]. - SKB264 has shown superior efficacy in various clinical settings, particularly in NSCLC, outperforming competitors in terms of mPFS [2][24]. - The collaboration with Merck enhances the global development strategy for SKB264, indicating strong commercial potential [1][15]. Summary by Sections Section 1: Collaboration and Clinical Development - The company has partnered with Merck to develop SKB264, which is currently in multiple Phase III clinical trials for various indications, including NSCLC and triple-negative breast cancer [14][15]. - SKB264 is recognized as a candidate with "blockbuster potential" by Merck, reflecting confidence in its market value [16]. Section 2: Efficacy in NSCLC - In the first-line treatment of wild-type NSCLC, SKB264 demonstrated a median progression-free survival (mPFS) of 15.0 months, significantly better than other TROP2 ADCs [2][24]. - In patients with PD-L1 TPS ≥1%, the mPFS reached 17.8 months, showcasing its effectiveness in this subgroup [2][24]. - SKB264 also exhibited promising results in EGFR-mutated NSCLC patients, with a notable reduction in tumor size compared to standard treatments [3][36]. Section 3: Future Potential and Market Position - The report highlights the potential of combining next-generation immunotherapy with ADCs, positioning SKB264 as a key player in this evolving treatment landscape [4][19]. - The competitive landscape for TROP2 ADCs is intensifying, with SKB264 among the leading candidates, necessitating close monitoring of upcoming clinical data [19][21]. Section 4: Financial Projections - Revenue forecasts for the company are optimistic, with projected revenues of 2.084 billion, 2.876 billion, and 4.663 billion CNY for 2025, 2026, and 2027 respectively [5][7]. - The company is expected to achieve profitability by 2027, with a projected net profit of 561 million CNY [5].